Saving lives: long-term morbidity and mortality trials with selective angiotensin receptor blocker therapy

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Drug treatment for hypertension is proven effective in reducing cardiovascular events.
• Conventional antihypertensive agents achieve benefits consistent with blood pressure reduction.
• Newer antihypertensive drug classes, such as angiotensin II receptor blockers (ARBs), are being investigated for additional therapeutic advantages.

Purpose of the Study:

• To evaluate the benefits of drug treatment for hypertension.
• To assess the potential advantages of novel antihypertensive agents beyond blood pressure control.
• To determine the future role of angiotensin II receptor blockers in managing hypertension.

Main Methods:

• Analysis of prospective randomized trials on hypertension drug treatment.
• Review of epidemiological data correlating blood pressure reduction with cardiovascular event incidence.
• Monitoring of ongoing long-term morbidity and mortality trials, including the VALUE trial.

Main Results:

• Established antihypertensive drugs convincingly demonstrate benefits in reducing cardiovascular events.
• The benefits observed align with expected outcomes based on achieved blood pressure differences.
• Emerging data suggests potential for angiotensin II receptor blockers to provide benefits beyond blood pressure lowering.

Conclusions:

• Drug therapy for hypertension is a cornerstone of cardiovascular risk reduction.
• Angiotensin II receptor blockers represent a promising class of antihypertensives with potential for broader benefits.
• Results from ongoing large-scale trials will be critical in defining the future clinical utility of ARBs.